Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire

被引:4
|
作者
Meazza, Raffaella [1 ]
Ruggeri, Loredana [2 ]
Guolo, Fabio [3 ,4 ]
Minetto, Paola [4 ]
Canevali, Paolo [1 ]
Loiacono, Fabrizio [1 ]
Ciardelli, Sara [2 ]
Bo, Alessandra [5 ]
Luchetti, Silvia [5 ]
Serio, Alberto [5 ]
Zannoni, Letizia [6 ]
Retiere, Christelle [7 ]
Colomar-Carando, Natalia [1 ]
Parisi, Sarah [8 ]
Curti, Antonio [8 ]
Lemoli, Roberto M. M. [3 ,4 ]
Pende, Daniela [1 ]
机构
[1] IRCCS Osped Policlin San Martino, Unita Operativa UO Immunol, Genoa, Italy
[2] Univ Perugia, Osped St Maria Misericordia, Dipartimento Med, Div Ematol & Immunol Clin, Perugia, Italy
[3] Univ Genoa, Dipartimento Med Interna DiMI, Clin Ematol, Genoa, Italy
[4] IRCCS Osped Policlin San Martino, Dipartimento Ematol & Oncol, Genoa, Italy
[5] IRCCS Osped Policlin San Martino, Lab Ctr Cellule Staminali & Terapie Cellulari, Genoa, Italy
[6] Univ Bologna, Dipartimento Med Specialist Diagnost & Sperimental, Bologna, Italy
[7] Univ Nantes, Inst Natl St & Rech Medicale INSERM, Ctr Natl Rech Sci CNRS, Ctr Rech Cance rol & Immunol Integree Nantes Anger, Nantes, France
[8] Univ Bologna, Ist Ematol Seragnoli, IRCCS Azienda Ospedaliero, Bologna, Italy
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
基金
欧盟地平线“2020”;
关键词
natural killer cells (NK cells); donor selection; NK alloreactivity; killer immunoglobulin-like receptors (KIR); human leucocyte antigen (HLA); adoptive immunotherapy; acute myeloid leukemia (AML); ACUTE MYELOID-LEUKEMIA; CLASS-I MOLECULES; NATURAL-KILLER-CELLS; INHIBITORY RECEPTOR; MHC MOLECULES; MISSING SELF; KIR; KIR3DL1; DIVERSITY; ALLELES;
D O I
10.3389/fimmu.2023.1111419
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Natural killer (NK) cell-based adoptive immunotherapy in leukemia patients is an emerging field of interest based on clinical evidence of efficacy and safety. Elderly acute myeloid leukemia (AML) patients have been successfully treated with NK cells from HLA-haploidentical donors, especially when high amounts of alloreactive NK cells were infused. The aim of this study was comparing two approaches to define the size of alloreactive NK cells in haploidentical donors for AML patients recruited in two clinical trials with the acronym "NK-AML" (NCT03955848), and "MRD-NK". The standard methodology was based on the frequency of NK cell clones capable of lysing the related patient-derived cells. The alternative approach consisted of the phenotypic identification of freshly derived NK cells expressing, as inhibitory receptors, only the inhibitory KIR(s) specific for the mismatched KIR-Ligand(s) (HLA-C1, HLA-C2, HLA-Bw4). However, in KIR2DS2(+) donors and HLA-C1(+) patients, the unavailability of reagents staining only the inhibitory counterpart (KIR2DL2/L3) may lead to an underestimated identification of the alloreactive NK cell subset. Conversely, in the case of HLA-C1 mismatch, the alloreactive NK cell subset could be overestimated due to the ability of KIR2DL2/L3 to recognize with low-affinity also HLA-C2. Especially in this context, the additional exclusion of LIR1-expressing cells might be relevant to refine the size of the alloreactive NK cell subset. We could also associate degranulation assays, using as effector cells IL-2 activated donor peripheral blood mononuclear cells (PBMC) or NK cells upon co-culture with the related patient target cells. The donor alloreactive NK cell subset always displayed the highest functional activity, confirming its identification accuracy by flow cytometry. Despite the phenotypic limitations and considering the proposed corrective actions, a good correlation was shown by the comparison of the two investigated approaches. In addition, the characterization of receptor expression on a fraction of NK cell clones revealed expected but also few unexpected patterns. Thus, in most instances, the quantification of phenotypically defined alloreactive NK cells from PBMC can provide data similar to the analysis of lytic clones, with several advantages, such as a shorter time to achieve the results and, perhaps, higher reproducibility/feasibility in many laboratories.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands
    Sanchez-Correa, Beatriz
    Morgado, Sara
    Gayoso, Inmaculada
    Bergua, Juan M.
    Casado, Javier G.
    Jose Arcos, Maria
    Luisa Bengochea, Maria
    Duran, Esther
    Solana, Rafael
    Tarazona, Raquel
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (08) : 1195 - 1205
  • [22] EFFECT OF GLUCAN ON NATURAL KILLER (NK) CELLS - FURTHER COMPARISON BETWEEN NK-CELL AND BONE-MARROW EFFECTOR CELL ACTIVITIES
    LOTZOVA, E
    GUTTERMAN, JU
    JOURNAL OF IMMUNOLOGY, 1979, 123 (02): : 607 - 611
  • [23] Natural Killer Cell Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Elimination of Donor-Derived Mature Alloreactive NK Cells, but Favorable Conditions for Adoptive Immunotherapy
    Russo, Antonio
    Oliveira, Giacomo
    Berglund, Sofia
    Greco, Raffaella
    Gambacorta, Valentina
    Cieri, Nicoletta
    Toffalori, Cristina
    Zito, Laura
    Piemontese, Simona
    Morelli, Mara
    Giglio, Fabio
    Assanelli, Andrea Angelo
    Stanghellini, Maria Teresa Lupo
    Bonini, Chiara
    Peccatori, Jacopo
    Luznik, Leo
    Ciceri, Fabio
    Vago, Luca
    BLOOD, 2016, 128 (22)
  • [24] Alloreactive Nk Cells to Augment Antileukemia Cytotoxicity with Allogeneic Stem Cell Transplantation for Aml/Mds: A Phase I Study
    Champlin, Richard
    Lee, Dean A.
    Fernandez-Vina, Marcelo
    Rondon, Gabriela
    McAdams, Patricia
    Juianne, Chen
    Qazilbash, Muzaffar H.
    Kebriaei, Partow
    Parmar, Simrit
    Shpall, Elizabeth J.
    Popat, Uday
    Alousi, Amin
    Ciurea, Stefan O.
    Cooper, Laurence
    Peter, Thall
    McMannis, John
    BLOOD, 2010, 116 (21) : 217 - 217
  • [25] Natural-killer cell (NK)-infusion as adoptive immunotherapy in patients with multiple myeloma relapsing after allogeneic stem cell transplantation
    Wolschke, C.
    Sputtek, A.
    Stuebig, T.
    Worthmann, F.
    van Randenborgh, A.
    Ayuk, F.
    Zander, A. R.
    Kroeger, N.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S198 - S198
  • [26] ENHANCED NATURAL KILLER (NK) AND NK T CELL ACTIVATION, EXPANSION AND CYTOKINE PROTEIN PRODUCTION FOLLOWING EX-VIVO ENGINEERING (EvE) OF PREVIOUSLY CRYOPRESERVED CORD BLOOD (CB): POTENTIAL FOR CB NK AND NK T CELLS IN ADOPTIVE CELLULAR IMMUNOTHERAPY (ACI)
    Ayello, J.
    Sugarman, E.
    Day, N.
    Hochberg, J.
    Mar, B.
    Cairo, E.
    van de Ven, C.
    Cairo, M. S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 42 - 43
  • [27] Development and function of NK and T cells in AML patients after allogeneic stem cell transplantation (SCT)
    Multhoff, G
    Gross, C
    Dickinson, A
    Holler, E
    BLOOD, 2004, 104 (11) : 886A - 886A
  • [28] NK-cell recovery and immune reconstitution after haploidentical hemalopoietic cell transplantation using either CD34 selected grafts and adoptive NK-cell transfer or CID3/CD19 depleted grafts: comparison of two strategies for NK cell based immunotherapy
    Gentilini, Chiara
    Haegele, Matthias
    Muessig, Arne
    Nogai, Axel
    Kliem, Constanze
    Bartsch, Kristina
    Bazara, Nadezda
    Vogel, Wichard
    Faul, Christoph
    Kanz, Lothar
    Thiel, Eckhard
    Niederwieser, Dietger W.
    Uharek, Lutz
    Bethge, Wolfgang A.
    BLOOD, 2007, 110 (11) : 877A - 877A
  • [29] Adoptive Transfer of Natural Killer (NK) Cells to Prevent Gvhd and Enhance GVT Effects After Allogeneic Hematopoietic Cell Transplantation (HCT): The Timing of Donor NK Cell Infusions Critically Impacts Transplant Outcome
    Lundqvist, Andreas
    Yokoyama, Hisayuki
    Childs, Richard W.
    BLOOD, 2009, 114 (22) : 325 - 325
  • [30] Ex Vivo IL-2 Expansion of CB-NK Cells Promotes Synergistic LFA-1 and CD2 Engagement at the NK Cell Lytic Immune Synapse; Implications for Adoptive CB-NK Cell Therapy in Acute Myeloid Leukemia.
    Xing, Dongxia
    Ramsay, Alan G.
    Decker, William
    Li, Sufang
    Robinson, Simon
    Yang, Hong
    Bollard, Catherine M.
    Gribben, John G.
    Shpall, Elizabeth J.
    BLOOD, 2009, 114 (22) : 1180 - 1181